BEDFORD, Mass. — Rejoni Inc. has appointed women’s health medical technology executive John Nealon as chief executive officer as the company advances its lead uterine health product toward potential FDA approval.
Rejoni, a privately held clinical-stage company based in Bedford, Mass., is developing biomaterial therapies for uterine health. Its lead product, the Juveena Hydrogel System, is a proprietary transcervical hydrogel implant designed to prevent the formation and reformation of intrauterine adhesions after gynecological procedures, including hysteroscopic surgery, dilation and curettage and fibroid removal.
Nealon brings more than 20 years of leadership experience in women’s health and medical devices. He most recently founded and led UroCure LLC, a Minneapolis-based medical device company focused on sling systems for female stress urinary incontinence. Rejoni said he guided UroCure through product development, FDA clearance, strategic partnerships and an acquisition by LiNA Medical.
Before UroCure, Nealon served as president and CEO of KSpine Inc., which was developing a surgical treatment for scoliosis. Earlier, he held senior leadership roles at American Medical Systems, including senior vice president and general manager of the company’s Women’s Health Business.
“As Rejoni advances toward FDA approval for the Juveena® Hydrogel System, I am thrilled to welcome John Nealon as our new CEO. His decades of experience leading women’s health businesses, his proven ability to navigate the complexities of medical device commercialization, and his genuine passion for improving outcomes for women make him the ideal leader to bring Rejoni into its next chapter. It has been a privilege to found and lead Rejoni since 2020, and I remain deeply committed to the mission as we work to ensure that no woman faces the burden of intrauterine adhesions without access to an effective solution. With John at the helm, I am confident we will drive Rejoni’s innovations to the women and clinicians who need them most,” said Amarpreet Sawhney, PhD, Founder and Chairman of Rejoni, Inc. and Managing Director of Pramand LLC.
Intrauterine adhesions can occur after certain gynecological procedures and may contribute to infertility, recurrent pregnancy loss and abnormal menstrual bleeding. Rejoni said the condition remains significantly underdiagnosed.
“I am honored and energized to join Rejoni at this pivotal moment in the company’s journey. Uterine health has been an underserved area for far too long, and Rejoni’s mission to protect, preserve, and heal the uterus resonates deeply with me. The Juveena Hydrogel System represents a truly differentiated approach to preventing intrauterine adhesions—a real and underrecognized burden for so many women. I look forward to partnering with Amar, the leadership team, and our investors to advance the Juveena Hydrogel System through the regulatory process and into the hands of physicians and patients who can benefit from it,” said Mr. Nealon.
The Juveena Hydrogel System is currently pending FDA approval and remains limited to investigational use.
